Biolife Solutions Stock Earnings Reports

Q1 2026 highlights: BioLife reported revenue of $27.5M, up 25% year-over-year, driven primarily by biopreservation media (BPM), which accounted for over 85% of revenue. Adjusted EBITDA was $6.2M (22% of revenue), down modestly as a percent of revenue due to bag yield/mix pressure. Management reiterated full-year 2026 guidance of $112.5M–$115M (17%–20% growth) and expects mid-60s percent GAAP/adjusted gross margins, expanded adjusted EBITDA margin, and full-year GAAP net income for the first time in many years. Operational notes: BPM is embedded in 17 approved therapies with visibility into 9 additional approvals/expansions; top 20 BPM customers provide strong revenue visibility and ~80% of BPM revenue; channel mix is ~60% direct sales. Key near-term operational issue is lower yields with bag products (lower margin than bottles), which management says is transitory; they are deploying customer options and expect margin benefit when existing bag inventory is burned through (targeting incremental improvement Q4 2026 or Q1 2027). Product & pipeline: cross-selling beyond BPM (CellSeal vials, hPL, CryoCase) is progressing—these products are in several validations and could meaningfully raise revenue per dose (management cites potential 2–3x uplift versus BPM alone); PanTHERA on track for a Q4 launch. Balance sheet & cash: cash and marketable securities $111.5M at 3/31/26 (down from $120.2M at year-end) after tax withholding, debt payments and working capital; $2.5M SVB debt is short-term with final payment due June 2026. Management remains focused on high-margin recurring revenue, selective M&A/partnerships, and operational fixes to restore margins. Risks: bag yield remediation timeline, inventory burn cadence, adoption cycles for new products (validation timelines), and concentration in top customers.